Roivant Sciences Ltd. (ROIV)
ROIVNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$40.55
+1.67 (+4.30%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $29.38bn
- P/E
- –
- EPS, last 4 quarters
- $-1.67
- Dividend yield
- –
- Day range
- –
- 52-week range
- $19.79 to $42.50
- Average volume
- 8.35m
- Previous close
- $38.88
Analysts
11 coveringBuy9 buy, 2 hold, 0 sell
Targets a year out average $49.00, +20.8% from here
Earnings
next estimate $-0.5200Next report
Sep 2025
-17.6%
Dec 2025
+7.7%
Mar 2026
-21.1%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $1.57m | $2.00m | $2.52m | $1.44m |
| Gross profit | $1.46m | $1.30m | $2.20m | $1.16m |
| Operating income | -$306.23m | -$339.15m | $415.24m | -$365.99m |
| Net income | -$113.52m | -$265.89m | $302.99m | -$189.84m |
Last four quarters: revenue $7.53m, margin -3535.0%, free cash flow -$821.06m
News
8 latest- Stock Indexes Surge as Buyers Return to Chipmakers and AI StocksBarchart · 2 minutes ago
- Stock Indexes Sharply Higher as Tech Stocks Rally and Crude Oil FallsBarchart · 2 hours ago
- Strength in Tech and Weakness in Crude Oil Boost StocksBarchart · 2 hours ago
- Roivant Sciences (ROIV) Q2 2026 Earnings Call TranscriptThe Motley Fool · 4 hours ago
- Roivant Sciences Ltd. Reports Financial Results for the Second Quarter Ended September 30, 2026Fintel · 9 hours ago
- Roivant Sciences Ltd. (ROIV) Reports Q2 Loss, Tops Revenue EstimatesZacks · 13 hours ago
- Voyager Therapeutics (VYGR) Reports Q3 Loss, Lags Revenue EstimatesZacks · 4 days ago
- Alkermes (ALKS) Surpasses Q3 Earnings and Revenue EstimatesZacks · 7 days ago
The company
Roivant (Nasdaq: ROIV) is a commercial-stage biopharmaceutical company that aims to improve the lives of patients by accelerating the development and commercialization of medicines that matter. Roivant's pipeline includes LISRAYA (brepocitinib), a potent small molecule inhibitor of JAK1 and TYK2 FDA-approved for the treatment of dermatomyositis in adult patients and also in late-stage development for the treatment of non-infectious uveitis, cutaneous sarcoidosis and lichen planopilaris; IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; and mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease. We advance our pipeline by creating nimble subsidiaries or 'Vants' to develop and commercialize our medicines and technologies.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- Europe
- Website
- roivant.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.